Skip to main content
SpringerLink
Log in

Modulation of CXC-motif chemokine receptor 7, but not 4, expression is related to migration of the human prostate cancer cell LNCaP: regulation by androgen and inflammatory stimuli

  • Original Research Paper
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

Objective

To elucidate the regulation, function of the chemokine CXC-motif ligand 12 (CXCL12) and its receptors (CXCR) 4 and 7 in prostate cancer tumor microenvironment.

Material

In-silico-analysis of expression in prostate cancer tissues. In-vitro comparison, testing of regulation in human prostate cancer cells LNCaP, DU145, and PC3.

Treatment

Dihydrotestosterone (DHT) treatments (0–10 nM) were for 0–48 h. The inflammatory agent Flagellin treatment (20 ng/ml) was for 2 h. Migration assays were performed for 24 h using 10 ng/ml CXCL12.

Methods

Real-time PCR, western analysis, and migration assays were used to determine mRNA, protein, and functional changes, respectively.

Results

Malignant prostate cancer tissues exhibit higher CXCR4/7 mRNA ratio, and higher CXCR7 mRNA levels were detected in the androgen-responsive LNCaP cells. Putative androgen-responsive elements were identified in CXCR4, 7 gene, and exposure to DHT, flagellin increased CXCR4 mRNA but decreased CXCR7 mRNA levels in LNCaP cells. Androgen receptor siRNA significantly attenuated the effects of DHT on CXCR4, 7 mRNA in LNCaP cells. However, DHT and flagellin only decrease CXCR7 protein and additively increased migration of LNCaP cells towards CXCL12.

Conclusions

Down regulation of CXCR7 protein by DHT and flagellin increased migration, supporting CXCR7 as decoy receptor counteracting CXCL12/CXCR4-mediated migration in prostate cancer cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30:195–200.

    Article  Google Scholar 

  2. Lubeck DP, Grossfeld GD, Carroll PR. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology. 2001;58:94–9.

    Article  CAS  Google Scholar 

  3. Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y, Fuse H. Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci. 2008;99:539–42.

    Article  CAS  Google Scholar 

  4. Chung LW, Baseman A, Assikis V, Zhau H. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol. 2005;173:10–20.

    Article  Google Scholar 

  5. Wang JH, Shiozawa Y, Wang JC, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem. 2007;283:4283–94.

    Article  Google Scholar 

  6. Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD, Cher ML. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res. 2008;6:446–57.

    Article  CAS  Google Scholar 

  7. Sánchez-Martín L, Estecha A, Samaniego R, Sánchez-Ramón S, Vega MÁ, Sánchez-Mateos P. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood. 2011;117:88–97.

    Article  Google Scholar 

  8. Rigo A, Gottardi M, Zamò A, et al. Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer. 2010;9:273.

    Article  Google Scholar 

  9. Ray P, Stacer AC, Fenner J, et al. CXCL12-γ in primary tumors drives breast cancer metastasis. Oncogene. 2015;34:2043–51.

    Article  CAS  Google Scholar 

  10. Sun YX, Wang JC, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 2003;89:462–73.

    Article  CAS  Google Scholar 

  11. Roy I, Zimmerman NP, Mackinnon AC, Tsai S, Evans DB, Dwinell MB. CXCL12 Chemokine expression suppresses human pancreatic cancer growth and metastasis. PLoS ONE. 2014;9:e90400.

    Article  Google Scholar 

  12. Singh S, Singh UP, Grizzle WE, Lillard JW Jr. CXCL12–CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 2004;84:1666–76.

    Article  CAS  Google Scholar 

  13. Chinni SR, Sivalogan S, Dong Z, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 express ion in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate. 2006;66:32–48.

    Article  CAS  Google Scholar 

  14. Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006;203:2201–13.

    Article  CAS  Google Scholar 

  15. Zheng K, Li HY, Su XL, et al. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Canc Res. 2010;29:31.

    Article  Google Scholar 

  16. Rajagopal S, Kim J, Ahn S, et al. β-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7. PNAS. 2010;107:2628–32.

    Article  Google Scholar 

  17. Singh RK, Lokeshwar BL. The IL-8–regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res. 2011;71:3268–77.

    Article  CAS  Google Scholar 

  18. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.

    Article  CAS  Google Scholar 

  19. Yu L, Chen SW. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother. 2008;57:1271–8.

    Article  CAS  Google Scholar 

  20. Caruso C, Balistreri CR, Candore G, et al. Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach. Cancer Immunol Immunother. 2009;58:1919–33.

    Article  CAS  Google Scholar 

  21. Galli R, Starace D, Busà R, et al. TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types. J Immunol. 2010;184:6658–69.

    Article  CAS  Google Scholar 

  22. Hajishengallis G. Immune evasion strategies of porphyromonas gingivalis. J Oral Biosci. 2011;53:233–40.

    Article  CAS  Google Scholar 

  23. Rieber N, Brand A, Hector A, et al. Flagellin induces myeloid-derived suppressor cells: implications for Pseudomonas aeruginosa infection in cystic fibrosis lung disease. J Immunol. 2013;190:1276–84.

    Article  CAS  Google Scholar 

  24. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118–26.

    Article  CAS  Google Scholar 

  25. Wang TTY, Hudson TS, Wang TC, et al. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis. 2008;29:2001–100.

    Article  CAS  Google Scholar 

  26. Kim EK, Kim YS, Milner JA, Wang TTY. Indole-3-carbinol and 3′,3′-diindolylmethane modulate androgen's effect on C-C Chemokine ligand 2 and monocyte attraction to prostate cancer cells. Cancer Prev Res. 2013;6:519–29.

    Article  CAS  Google Scholar 

  27. Peng H, Erdmann N, Whitney N, et al. HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1β. GLIA. 2006;54:619–29.

    Article  Google Scholar 

  28. Huang HQ, Fletcher A, Niu YG, Wang TTY, Yu LL. Characterization of lipopolysaccharide-stimulated cytokine expression in macrophages and monocytes. Inflamm Res. 2012;61:1329–38.

    Article  CAS  Google Scholar 

  29. Wang TTY, Schoene NW, Kim YS, Mizuno CS, Rimando AM. Differential effects of resveratrol and its naturally occurring methylether analogs on cell cycle and apoptosis in human androgen-responsive LNCaP cancer cells. Mol Nutr Food Res. 2010;54:335–44.

    Article  CAS  Google Scholar 

  30. Veldscholte J, Berrevoets CA, Ris-Stalpers C, et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol. 1992;41:665–9.

    Article  CAS  Google Scholar 

  31. Trasino SE, Harrison EH, Wang TTY. Androgen regulation of aldehyde dehydrogenase 1A3 (ALDH1A3) in the androgen-responsive human prostate cancer cell line LNCaP. Exp Biol Med. 2007;232:762–71.

    CAS  Google Scholar 

  32. Niu YJ, Altuwaijri S, Lai KP, et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA. 2008;105:12182–7.

    Article  CAS  Google Scholar 

  33. Li T, Li D, Sha JJ, Sun P, Huang YR. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun. 2009;383:280–5.

    Article  CAS  Google Scholar 

  34. Hoy JJ, Kallifatidis G, Smith DK, Lokeshwar BL. Inhibition of androgen receptor promotes CXC-chemokine receptor 7-mediated prostate cancer cell survival. Sci Rep. 2017;7(1):3058.

    Article  Google Scholar 

  35. Wang JH, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev. 2006;25:573–87.

    Article  CAS  Google Scholar 

  36. Uygur B, Wu WS. SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis. Mol Cancer. 2011;10:139.

    Article  CAS  Google Scholar 

  37. Lee C, Sutkowski DM, Sensibar JA, et al. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinol. 1995;136:796–803.

    Article  CAS  Google Scholar 

  38. Fürstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet. 2002;3:298–302.

    Article  Google Scholar 

  39. Zhu ML, Kyprianou N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J. 2009;24:769–79.

    Article  Google Scholar 

  40. Palapattu GS, Sutcliffe S, Bastian PJ, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis. 2005;26:1170–81.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Dr. Norberta Schoene for her comments and editorial assistance. This study was supported by US Department of Agriculture appropriated fund #8040–51530-057-00D

Author information

Authors and Affiliations

  1. Department of Nutrition and Food Science, University of Maryland, College Park, MD, 20742, USA

    Lu Yu & Liangli Lucy Yu

  2. Diet, Genomics and Immunology Laboratory, Beltsville Human Nutrition Research Center, ARS, USDA, 10300 Baltimore Ave., Bldg. 307C, Rm 132, Beltsville, MD, 20705, USA

    Quynhchi Pham & Thomas T. Y. Wang

Authors
  1. Lu Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Quynhchi Pham
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liangli Lucy Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas T. Y. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas T. Y. Wang.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Responsible Editor: John Di Battista.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 10661 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, L., Pham, Q., Yu, L.L. et al. Modulation of CXC-motif chemokine receptor 7, but not 4, expression is related to migration of the human prostate cancer cell LNCaP: regulation by androgen and inflammatory stimuli. Inflamm. Res. 69, 167–178 (2020). https://doi.org/10.1007/s00011-019-01305-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-019-01305-0

Keywords

Search

Navigation